Randolf Kerschbaumer, Michael Thiele and Alexander Schinagl (OncoOne)
March 18, 2020 06:01 AM EDTUpdated 07:34 AM
Financing
Startups

For­mer Shire ex­ecs set up shop to take a shot at 'un­der the radar' can­cer tar­get

Natalie Grover

Reporter

In De­cem­ber 2016, Shire aban­doned a can­cer drug tar­get­ing oxMIF it had swal­lowed as part of its $32 bil­lion buy­out of Bax­al­ta ear­li­er that year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times